CADENCE
LIVE

Serial Number

79366831

Owner

MIRXES PTE. LTD.

Attorney

Joseph G. Chu

Filing Date

Jan 18, 2023

Add to watchlist:

No watchlists yet
View on USPTO

CADENCE Trademark

Serial Number: 79366831

CADENCE is a trademark filed by MIRXES PTE. LTD. on January 18, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

MIRXES PTE. LTD. (6 trademarks)

2 TUKANG INNOVATION GROVE,

Entity Type: 24

Trademark Details

Filing Date

January 18, 2023

Registration Date

Not Registered

Goods & Services

Medical diagnostic services, namely, testing and analysis; medical testing services relating to the diagnosis and treatment of disease; medical analysis services for the diagnosis of cancer; Medical services, namely, nucleic acid analysis for cancer diagnosis and prognosis; performing diagnosis of diseases; medical services for the diagnosis of conditions of the human body; genetic testing of animals for diagnostic or treatment purposes; medical laboratory services related to the treatment of patients; Medical advisory services in the field of oncological diseases; medical analysis for the diagnosis and treatment of persons; Medical services, namely, health risk assessment surveys; health-care services for treating and detecting cancer; genetic testing for medical purposes; Medical services, namely, nucleic acid screening for medical purposes; Medical analysis services for diagnosing and detecting cancer; medical screening; Health screening services in the field of cancer; all of the foregoing related to cancer screening and diagnostic tests

Diagnostic preparations for medical and veterinary use or purposes; Medical diagnostic reactants for medical and veterinary diagnosis of diseases; diagnostic preparations for medical use for sale in kit form; diagnostic preparations for medical purposes; Biological indicators for medical diagnosis, namely, for detecting and diagnosing cancer; veterinary diagnostic reagents; Diagnostic reagents in kit form for conducting molecular biology assays for medical or veterinary purposes; Diagnostic reagents for medical or veterinary purposes; Diagnostic reagents for use in diagnostic tests for medical or veterinary purposes; pharmaceutical preparations for the treatment of disorders of the metabolic system; medical diagnostic reagents for testing of body fluids; Medical diagnostic assays that test for genetic anomalies for medical use; Diagnostic preparations for medical use; Biochemical preparations for diagnostic use for detecting and diagnosing cancer; Diagnostic preparations for medical purposes; Diagnostic agents for pharmaceutical use in the medical field; Test reagents for medical diagnosis, namely, disease testing; diagnostic biomarker reagents for medical purposes; Chemical preparations for diagnostic medical purposes, namely, for detecting and diagnosing cancer; Chemical preparations for use in medical diagnostics, namely, nucleic acid analysis; Chemical preparations for detecting genetic and epigenetic predispositions for medical purposes; Medical diagnostic reagents for analysis of body fluids; Synthetic deoxyribonucleic acid and synthetic ribonucleic acid for medical use, namely, for detecting and diagnosing cancer; nucleic acid amplification reagents for medical use; all of the foregoing related to cancer screening and diagnostic tests

Medical diagnostic apparatus for detecting and diagnosing cancer; Medical diagnostic instruments for analysis of body fluids; Biomedical testing apparatus for RNA, DNA and protein biomarkers testing; Medical diagnostics instruments in the nature of apparatus for testing RNA, DNA and protein biomarkers; medical instruments for infectious disease testing; Medical diagnostic testing apparatus for sale in kit form for testing RNA, DNA and protein biomarkers for diagnosing and detecting cancer; Medical diagnostic apparatus for testing RNA, DNA and protein biomarkers for diagnosing and detecting cancer; Diagnostic in-vitro diagnostic testing apparatus for medical use for diagnosing and detecting cancer; Medical diagnostic testing apparatus for use in molecular biology procedures, namely, testing DNA, RNA and protein biomarkers for diagnosing and detecting cancer; Diagnostic apparatus for blood tests for medical use; all of the foregoing related to cancer screening and diagnostic tests

Filing History

REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
May 19, 2026 RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Sep 23, 2025 RCSC
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Aug 27, 2025 RCCK
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Feb 26, 2025 RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Jan 27, 2025 RCSC
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Sep 20, 2024 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Sep 4, 2024 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Sep 4, 2024 OPNR
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Apr 30, 2024 GNS3
LETTER OF SUSPENSION E-MAILED
Apr 30, 2024 GNSL
SUSPENSION LETTER WRITTEN
Apr 30, 2024 CNSL
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Apr 26, 2024 AMPX
TEAS VOLUNTARY AMENDMENT RECEIVED
Apr 26, 2024 PARI
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 26, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 26, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 26, 2024 TROA
REFUSAL PROCESSED BY IB
Nov 22, 2023 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Oct 27, 2023 RFCS
REFUSAL PROCESSED BY MPU
Oct 27, 2023 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Oct 20, 2023 RFCR
NON-FINAL ACTION WRITTEN
Oct 19, 2023 CNRT
ASSIGNED TO EXAMINER
Oct 17, 2023 DOCK
APPLICATION FILING RECEIPT MAILED
Apr 14, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 10, 2023 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Apr 6, 2023 REPR